Concepedia

Publication | Open Access

LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

DOIFull Paper Access

55

Citations

0

References

2022

Year

Hope S. Rugo, A. Bardia, F. Marmé, J. Cortés, P. Schmid, D. Loirat, Olivier Trédan, E.M. Ciruelos, F. Dalenc, P. Gomez Pardo,
Annals of Oncology

No additional data available for this publication yet. Check back later!